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ABSTRACT
Background. Automated acute kidney injury (AKI) electronic alerts (e-alerts) are rule-based warnings triggered by changes in
creatinine and are intended to facilitate earlier detection in AKI. We assessed the impact of the introduction in the Tayside
region of UK in April 2015 of automated AKI e-alerts with an accompanying education programme.
Methods. Interrupted time-series analysis using segmented regression was performed involving all adults with AKI aged
18 years who had a serum creatinine measured between 1 April 2013 and 31 March 2017. Analysis evaluated associations
of AKI e-alert introduction on rate and severity (Stages 2–3) of AKI as well as mortality and occupied hospital bed days per
patient per month in the population with AKI.
Results. There were 32 320 episodes of AKI during the observation period. Implementation of e-alerts had no effect on the
rate of any AKI [incidence rate ratio (IRR) 0.996, 95% confidence interval (CI) 0.991 to 1.001, P¼0.086] or on the rate of severe
AKI (IRR 0.995, 95% CI 0.990 to 1.000, P¼0.061). Subgroup analysis found no impact on the rate or severity of AKI in hospital
or in the community. Thirty-day mortality following AKI did not improve (IRR 0.998, 95% CI 0.987 to 1.009, P¼0.688). There
was a slight reduction in occupied bed days (b-coefficient 0.059, 95% CI 0.094 to 0.025, P¼0.002).
Conclusions. Introduction of automated AKI e-alerts was not associated with a change in the rate, severity or mortality
associated with AKI, but there was a small reduction in occupied hospital bed days.
Keywords: AKI, electronic alert, epidemiology, mortality, patient outcomes
INTRODUCTION
Acute kidney injury (AKI) affects 13–18% of all patients admitted
to hospital [1]. There is increasing evidence showing that even
mild, transient episodes of AKI are associated with adverse out-
comes such as increased risk of death [2–4] and development of
chronic kidney disease [5]. Once established, there are no
proven effective treatments for AKI, although delays in diagno-
sis are associated with poorer outcomes [6]. The emphasis in
policy is therefore prevention and earlier recognition. Electronic
alerts (e-alerts) are automated alerts triggered by changes in se-
rum creatinine that are intended to enable earlier detection of
AKI and therefore expedite management. The effect of e-alerts
on AKI for hospitalized patients remains unclear, with conflict-
ing results from several studies [7, 8]. In the UK, there has been
a national initiative aimed at improving the care of patients at
risk for or with AKI [1, 9]. As part of this initiative, the National
Health Service (NHS) in England mandated that all hospitals im-
plement an e-alert for AKI based on the Kidney Disease:
Improving Global Outcomes (KDIGO) definition for AKI [10].
In April 2015, the NHS Tayside region of Scotland introduced
AKI e-alerts simultaneously for all patients in primary and sec-
ondary care. The e-alerts are generated by the laboratory report-
ing system using the same rules as the NHS England e-alerts.
The AKI stage appears with creatinine results alongside a link
that was added to signpost clinicians to local AKI guidelines.
New guidelines tailored for primary care were created to supple-
ment the AKI in hospital guidance that was already in place.
These guidelines cover the assessment, investigations and
management of patients with AKI including indications for re-
ferral to the renal team, and are available as supplementary fig-
ures (Supplementary data, Figures S1 and S2). The banner with
the patients identifying information changes colour when an e-
alert has been triggered, further highlighting to the clinician
reviewing the results that an AKI has been detected. An auto-
mated email is also sent to clinicians for all AKI Stages 2 and 3.
This was accompanied by both a community- and hospital-
wide education programme aimed at raising awareness of AKI.
An AKI awareness week was organized for the week preceding
the introduction of the AKI e-alerts, with teaching carried out
for junior doctors and nursing staff on every ward as well as
through departmental meetings, hospital grand rounds and a
stand at the main hospital entrance. An educational video [11]
and lanyard cards [12] were also developed.
The aim of this study was to assess the impact of AKI e-
alerts on patient outcomes by examining the rate and severity




The study population comprised of all adults aged 18 years
who were not receiving renal replacement therapy, and who
had a creatinine measurement between 1 April 2013 and
31 March 2017 who resided in the NHS Tayside region of
Scotland, UK.
Data sources
Data were provided by the Health Informatics Centre (HIC) at
the University of Dundee [13]. HIC links individual patient data
by means of the unique identifier used across NHS Scotland
[the Community Health Index (CHI) number]. Data from the fol-
lowing datasets were linked: CHI register for patient demogra-
phy; Scottish Morbidity Record of hospital admissions (SMR01)
for length of inpatient stay; Scottish Renal Registry (SRR) to ex-
clude people on renal replacement therapy [14]; the NHS labora-
tory providing all biochemistry measurement in Tayside for
creatinine; and the General Registry Office (GRO) national death
registration system for mortality. Community-acquired AKI was
defined as occurring in the community or on the first day of
hospital admission. Hospital-acquired AKI included all episodes
of AKI that occurred during a hospital admission, excluding
those that were first detected prior to admission or during the
first 24 h of admission.
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Outcomes
For both NHS e-alerts and study outcomes, the diagnosis and
stage of AKI were defined using the NHS England e-alert algo-
rithm , which is based on the KDIGO creatinine-based criteria
[10, 15]. Baseline creatinine was defined as either the median of
all creatinine measurements taken between 8 and 365 days
prior to the index creatinine measurement or the minimum cre-
atinine taken in the preceding 7 days before the index creatinine
measurement. AKI Stage 1 was defined as an increase in serum
creatinine between 150% and <200% of baseline or a rise in se-
rum creatinine of 26.5 lmol/L in 2 days; AKI Stage 2 was de-
fined as an increase in serum creatinine between 200% and
<300% of the baseline value; and AKI Stage 3 was defined as an
increase in serum creatinine to 300% of baseline value or a se-
rum creatinine of 354 mmol/L. AKI episodes were counted as
unique events if there were >7 days between e-alerts being trig-
gered. AKI stage was defined by the highest stage experienced
during each AKI episode. We examined the impact of the intro-
duction of AKI e-alerts on the total rate of AKI, and on the rate
of severe AKI (Stages 2–3). Subgroup analysis was performed
to establish whether e-alerts differentially affected rates of
community-acquired AKI or hospital-acquired AKI.
Mortality within 30 days and 90 days of the occurrence of the
highest stage of AKI episode was examined using death regis-
tration data from the General Register of Deaths. In those
admissions where there was an AKI detected, length of stay
was calculated using number of occupied bed days per patient.
Occupied bed days for people admitted with AKI were summed
for each month, and divided by the number of individuals with
AKI who contributed to these stays to obtain the bed days per
patient per month.
Statistical methods
The study design was an observational cohort study with seg-
mented regression analysis of interrupted time-series (ITS) data
[16]. We used 25 monthly time points before and 23 time points
after the introduction of AKI e-alerts in April 2015 to assess the
impact of the intervention in terms of both immediate impact
(change in level of the outcome immediately after the interven-
tion) and gradual impact (change in trend after the interven-
tion). For all analyses, the presence of autocorrelation was
evaluated using the Durbin–Watson statistic, and accounted for
if necessary, by fitting a lagged variable.
The impact of the intervention on the number of unique AKI
events per month was analysed using a Poisson segmented re-
gression model. The impact of the intervention on death within
30 days and within 90 days was also analysed using a Poisson
model where the total unique AKI episodes per month were
used as an offset, converting the model outcome into a rate.
The impact of the intervention on occupied bed days per month
per patient with AKI was examined using a linear segmented re-
gression model. All analyses were carried in IBM SPSS (v22), R
















































































































FIGURE 1: Monthly count of all AKI and severe AKI (Stages 2–3) between 1 April 2013 and 31 March 2017 in NHS Tayside.
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Ethical approval
Anonymized record linkage was conducted according to HIC
Standard Operating Procedures (SOPs). The Tayside Research
Ethics Committee does not require submission of individual
studies that follow HIC SOPs, which are Caldicott Guardian ap-
proved. All data used in the project were secured on a Scottish
Government accredited and ISO27001 certified safe haven.
RESULTS
Between 1 April 2013 and 31 March 2017, there were 32 320 sepa-
rate episodes of AKI in 19 924 eligible individuals aged 18 years
and not on renal replacement therapy (RRT). Of these, 21 712
(67.2%) were AKI Stage 1, 4880 (15.1%) were AKI Stage 2 and 5728
(17.7%) were AKI Stage 3 (Table 1). The mean number of AKI epi-
sodes per month was 673 (SD 41). The mean age of patients at
each AKI episode was 71.0 (SD 16.9) and 52% were female.
Totally, 18 227 AKI episodes occurred in the community and
14 093 were acquired in hospital. The overall mortality within
30 days and 90 days of an episode of AKI was 15.9% and 22.8%,
respectively.
AKI
Results from the segmented regression analysis showed there
were no prior trends up or down in any of the outcomes.
Following the intervention, there was no evidence of an imme-
diate impact, known as the level change, on the rate of AKI in-
tervention [incidence rate ratio (IRR) 0.972, 95% confidence
interval (CI) 0.908–1.041]. There was also no change in the trend
of AKI rates (IRR 0.996 per month, 95% CI 0.991–1.001). Similarly,
there was no change in the level (IRR 1.005, 95% CI 0.934–1.081)
or trend (IRR 0.995 per month, 95% CI 0.990–1.000) of Stages 2–3
AKI (Table 2, Figure 1). Subgroup analysis found no change in
the rate of total AKI in the community (level change IRR 1.022,
95% CI 0.931–1.122; trend change IRR 0.998 per month, 95% CI
0.991–1.005) or in the rate of severe AKI in the community
(Stages 2–3 AKI IRR level change 1.037, 95% CI 0.945–1.138; trend
change IRR 0.996 per month, 95% CI 0.990–1.003). Similarly, for
hospital-acquired AKI, there was no change in the rate of total
AKI (level change IRR 0.929, 95% CI 0.841–1.027; trend change
IRR 0.994 per month, 95% CI 0.986–0.002) or in the rate of severe
AKI (Stage 2–3 IRR level change 0.939, 95% CI 0.815–1.082; trend
change 0.991 per month, 95% CI 0.981–1.001).
Mortality
There was no change in the 30-day mortality associated with an
AKI episode following the intervention (level change IRR 0.878,
95% CI 0.757–0.017, P¼ 0.091; trend change IRR 0.998, 95% CI
0.987–1.009, P¼ 0.688) (Figure 2A). Similarly, there was no
change in 90-day mortality (level change IRR 0.918, 95% CI
0.828–1.018, P¼ 0.111; trend change IRR 0.999, 95% CI 0.991–
1.006, P¼ 0.745) (Figure 2B).
Occupied hospital bed days
There was a small reduction in occupied bed days per patient
per month for patients with AKI following the implementation
of e-alerts (b-coefficient 0.059, 95% CI 0.094 to 0.025,
P¼ 0.002) (Figure 3).
DISCUSSION
In this large observational study of all AKI episodes in adults in
a population of >400 000 people over a 4-year period, we found
that the introduction of AKI e-alerts for patients in hospital and
in the community had no significant effect on the rate and se-
verity of AKI, or on the mortality associated with AKI. There
was a small reduction in occupied hospital bed days by people
with AKI, which may not be clinically significant.
Previous studies have suggested a benefit from using AKI e-
alerts on care processes including a reduction in time taken to
modify or discontinue medications [17], and an increase in fluid
assessments and prescribing in hospital [18, 19]. We have
shown in a previous study that the introduction of AKI e-alerts
in the community led not only to an increase in creatinine mon-
itoring [20], but also to higher rates of hospitalization. Several
studies have reported reductions in mortality associated with
AKI following the introduction of e-alerts [21, 22] but have eval-
uated impact using an uncontrolled before or after comparison,
which is at high risk of bias because it does not account for
any underlying trend in the data (unlike the ITS analysis used
in this study). In a single-centre randomized trial, evaluating
the impact of AKI e-alerts, Wilson et al. found no reduction in
mortality or in the need for renal replacement therapy [23].
Table 1. Characteristics of AKI
Community Hospital Total
n¼ 18 227 n¼ 14 093 n¼32 320
AKI Stage 1 10908 10804 21712
AKI Stage 2 2813 2067 4880
AKI Stage 3 4506 1222 5728
Mean (SD) age, years
AKI Stage 1 67.23 (19.1) 74.91 (14.7) 71.05 (17.4)
AKI Stage 2 70.44 (17.0) 73.39 (14.6) 71.69 (16.1)
AKI Stage 3 69.54 (15.8) 71.57 (14.6) 69.97 (15.6)
All AKI 68.30 (18.0) 74.39 (14.7) 70.96 (16.9)
Sex, M (%)/F (%)
AKI Stage 1 4605 (42.2)/6303 (57.8) 5277 (48.8)/5527 (51.2) 9882 (45.5)/11830 (54.5)
AKI Stage 2 1289 (45.8)/1524 (54.2) 953 (46.1)/1114 (53.9) 2242 (45.9)/2638 (54.1)
AKI Stage 3 2842 (63.1)/1664 (36.9) 652 (53.4)/570 (46.6) 3494 (61)/2234 (39)
All AKI 8736 (47.9)/9491 (52.1) 6882 (48.8)/7211 (51.2) 15618 (48.3)/16702 (51.7)
30-day mortality post AKI (%) 2201 (12.1) 2926 (20.8) 5127 (15.9)
90-day mortality post AKI (%) 3318 (18.2) 4048 (28.7) 7366 (22.8)






































































































































































FIGURE 2: Rate of (A) 30-day mortality and (B) 90-day mortality associated with AKI between 1 April 2013 and 31 March 2017 in NHS Tayside.
Table 2. Association of AKI e-alerts implementation with changes in AKI, mortality associated with AKI and occupied hospital days per patient
Variable Baseline trend Level change Trend change
Results using the Poisson model with number of unique AKI events as outcome
Total AKI episodes IRR (95% CI) 1.003 (0.999 to 1.006) 0.972 (0.908 to 1.041) 0.996 (0.991 to 1.001)
P-value 0.118 0.425 0.086
Stages 2–3 AKI episodes IRR (95% CI) 1.002 (0.999 to 1.006) 1.005 (0.934 to 1.081) 0.995 (0.990 to 1.000)
P-value 0.188 0.898 0.061
Community-acquired total AKI episodes IRR (95% CI) 1.001 (0.996 to 1.005) 1.022 (0.931 to 1.122) 0.998 (0.991 to 1.005)
P-value 0.793 0.645 0.616
Community-acquired Stages 2–3 AKI episodes IRR (95% CI) 1.002 (0.997 to 1.006) 1.037 (0.945 to 1.138) 0.996 (0.990 to 1.003)
P-value 0.477 0.450 0.311
Hospital-acquired total AKI episodes IRR (95% CI) 1.004 (0.999 to 1.009) 0.929 (0.841 to 1.027) 0.994 (0.986 to 1.002)
P-value 0.113 0.158 0.130
Hospital-acquired Stages 2–3 AKI episodes IRR (95% CI) 1.004 (0.997 to 1.011) 0.939 (0.815 to 1.082) 0.991 (0.981 to 1.001)
P-value 0.250 0.389 0.097
Results using Poisson model with number of deaths within 30 and 90 days from AKI detection as outcome
30-day mortality IRR (95% CI) 1.008 (0.999 to 1.016) 0.878 (0.757 to 1.017) 0.998 (0.987 to 1.009)
P-value 0.084 0.091 0.688
90-day mortality IRR (95% CI) 1.006 (1.000 to 1.012) 0.918 (0.828 to 1.018) 0.999 (0.991 to 1.006)
P-value 0.075 0.111 0.745
Results using the linear model with occupied hospital bed days per month per patient with AKI as outcome
Occupied hospital bed days Beta (95% CI) 0.015 (0.038 to 0.008) 0.774 (0.293 to 1.255) 0.059 (0.094 to 0.025)
P-value 0.200 0.003 0.002
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Selby et al. [24] conducted a pragmatic stepped wedge cluster
randomized trial in which e-alerts were introduced alongside
an AKI bundle and education programme across five UK hospi-
tals over sequential 3-month time periods. They found no im-
provement in 30-day mortality associated with AKI after the
intervention. Furthermore, they demonstrated a reduced length
of stay following the intervention, particularly in those with
longer admissions.
While early recognition of AKI is desirable, it remains
unclear whether AKI e-alerts improve patient outcomes. One
reason could be that e-alerts based solely on creatinine rise (like
the NHS England algorithm we used) are a late marker of dis-
ease since they may not rise until 48–72 h after kidney injury
[25]. Reduction in urine output precedes creatinine rise and is
part of the KDIGO diagnostic criteria for AKI, but is not recorded
in the community and is often poorly recorded in hospital.
Utilizing biomarkers that rise earlier in AKI may facilitate more
timely intervention [26] but are not yet widely available in clini-
cal practice. One study, however, examining the impact of AKI
e-alerts in patients who were also reviewed by critical care (but
based on physiological deterioration, not AKI) found that
patients reviewed on the day the e-alert was triggered had a sig-
nificantly improved mortality and reduction in need for RRT
compared with patients reviewed by critical care on any subse-
quent day [27]. This suggests that changes in serum creatinine
do provide a window of opportunity for intervention.
A second reason why e-alerts may not be effective is that
they do not actually change clinical practice. In the NHS Tayside
AKI e-alert, clinicians are encouraged to record their response,
but it is not mandatory. We tested the use of an AKI care bundle
in our acute medical admissions unit that used a sticker added
to the notes of patients with AKI to demonstrate their care was
in keeping with the guidance, but due to poor compliance, this
was not adopted in other areas [12]. Notably, the results system
delivering the AKI e-alert could continue to be used as normal
whether the AKI care bundle was completed or not. In a meta-
regression analysis, Roshanov et al. [28] found that requiring
clinicians to provide a reason for overriding advice significantly
improved the effectiveness of computerized clinical decision
support systems in changing processes of care. Kolhe et al. [29]
described an interruptive AKI e-alert that required clinicians to
complete an AKI care bundle before they could request further
blood tests or order medications unless a reason was given to
override the alert. They found that this e-alert improved com-
pliance with the AKI care bundle and that patients with the care
bundle complete had a lower mortality and reduced progression
of AKI to higher stages compared with a propensity score-
matched group of patients with AKI where the care bundle was
not complete [30]. McCoy et al. [31] examined the role of AKI e-
alerts on medications management and found that while pas-
sive alerts had no significant impact, interruptive alerts led to
medications being altered or discontinued more quickly.
Passive AKI e-alerts, including the one used in this study, may
be more likely to lead to alert fatigue, were clinicians exposed to
a large number of alerts become desensitized to them. Notably,
while no results reached statistical significance, the IRR was <1
for change in trend of AKI rates for all analyses (total AKI rate
and severe AKI rate in hospital and in the community). The
change in trend for severe AKI almost reached statistical signifi-
cance (IRR 0.995 per month, P¼ 0.061), driven particularly by the
impact on severe AKI in hospital (IRR 0.991 per month,
P¼ 0.097). Clinicians in the community do not routinely review
blood results on the day they are sent, so are less well placed to
respond an AKI e-alert in a timely manner. A more assertive, in-
terruptive e-alert may be more effective, particularly in AKI
Stage 1, where early intervention could prevent progression to
more severe AKI.
A strength of our study was that we used a robust quasi-
experimental design with a prolonged study period and clear in-
tervention time. This allowed us to control for trends before the
intervention and adjust for common biases such as seasonality
and autocorrelation. AKI was defined using the KDIGO defini-
tion and the rate and stage of AKI were calculated using all
available creatinine results from the study period, rather than
by simply counting e-alerts before and after the intervention.





































































































*Intercept: 13.820 (95% CI 13.478–14.161), P < 0.001
FIGURE 3: Bed days per patient per month for patients with AKI between 1 April 2013 and 31 March 2017 in NHS Tayside.
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Weaknesses include that we were unable to examine whether
AKI e-alerts led to changed management of people with AKI. In
addition, the population of the Tayside region of Scotland is
predominantly of European ancestry with relatively low levels
of ethnic diversity, which may limit the generalizability of our
findings.
CONCLUSION
We have demonstrated that the introduction of a whole-system
AKI e-alert and educational programme did not have a signifi-
cant impact on the rate, severity or mortality associated with
AKI. There was a small reduction in bed days per patient per
month for patients with AKI associated with e-alert introduc-
tion. Our findings are consistent with other evidence from a sin-
gle trial and other more robust observational studies, and add
to the literature by examining impact of AKI e-alerts in the com-
munity as well as in hospital in a defined geographical popula-
tion. Further research focusing on how AKI e-alerts alter
clinicians’ behaviour and an evaluation of the impact this has
on patient care is required to fully understand their effect on
outcomes. In addition, work on how the delivery of the e-alert
can be optimized is needed prior to further implementation.
Evaluation of more active alerts in Stage 1 AKI would be of par-
ticular value.
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